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Abstract: Continuous and flash glucose monitoring systems measure interstitial fluid glucose
concentrations within a body compartment that is dramatically altered by posture and is responsive
to the physiological and metabolic changes that enable exercise performance in individuals with type
1 diabetes. Body fluid redistribution within the interstitial compartment, alterations in interstitial
fluid volume, changes in rate and direction of fluid flow between the vasculature, interstitium and
lymphatics, as well as alterations in the rate of glucose production and uptake by exercising tissues,
make for caution when interpreting device read-outs in a rapidly changing internal environment
during acute exercise. We present an understanding of the physiological and metabolic changes taking
place with acute exercise and detail the blood and interstitial glucose responses with different forms
of exercise, namely sustained endurance, high-intensity, and strength exercises in individuals with
type 1 diabetes. Further, we detail novel technical information on currently available patient devices.
As more health services and insurance companies advocate their use, understanding continuous and
flash glucose monitoring for its strengths and limitations may offer more confidence for patients
aiming to manage glycemia around exercise.
Keywords: continuous glucose monitoring; flash glucose monitoring; exercise; interstitium
1. Introduction
Type 1 diabetes is characterized by the autoimmune destruction of pancreatic β-cells within the
islets of Langerhans and loss of endogenous insulin production. Most diagnoses are made early in life
and result in a life-long dependency on pharmacological insulin, carbohydrate counting, and frequent
blood glucose measurements to manage blood glucose levels [1]. In the United Kingdom, over a
quarter of a million people have type 1 diabetes and this number is rising. The cost to the National
Health Service (NHS) for treatment and care is approximately
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1. Introduction 
Type 1 diabetes is characterized by the autoimmune destr ction of pancreatic β- ells within the 
islets of Langerhans and loss of endogenous insulin production. Most diagnoses are mad  early in 
life and result in a life- ong dependency on pharmacological insulin, carbohydrate counting, an  
frequent  l  as re ents to anage blood glucose levels [1]. In the United Kingdom, 
over a quarter of a million people have type 1 diabetes and this nu ber is i .     
National          ₤1.8+ billion a year [2]. Low 
levels of physical activity are evident in people with type 1 diabetes [3] and large cohort studies 
demonstrate an increased risk of cardiovascular disease [4,5]; however, regular physical activity is 
advocated [6,7] and conveys important health benefits [8]. Nevertheless, the increased risk of 
developing hypoglycemia and the loss of glucose control around exercise are major concerns for 
people with type 1 diabetes, contributing to the failure to initiate or maintain regular physical  
activity [9]. 
li . levels of
ic l activity are vident in people with type 1 diabetes [3] and l rge cohort studie demonstrate an
increased risk of cardi vascular di ease [4,5]; however, regular physical activity is dvocated [6,7] and
conveys important health benefits [8]. Nevertheless, the inc eas d risk of developing hypoglycemia
and the loss of glucose control around exercise are major concerns for people with type 1 diabetes,
contributing to the failure to in tiate r maintain regular physical activity [9].
Frequent finger prick blood sampling and adjustments in exogenous basal and/or bolus insulin
and carbohydrate intake are necessary to minimize glycemic disturbances with physical exercise [6,7].
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However, mimicking the natural secretory pattern of endogenous insulin in individuals without
diabetes whilst maintaining glycemia within a normal physiological range is challenging around
exercise [6,10]. In the Diabetes Control and Complications Trial, intensive treatment to maintain
euglycemia between 4 and 7 mmol/L with either an external insulin pump or three or more daily
insulin injections and frequent blood glucose measurements delayed the onset and slowed the
progression of retinopathy, nephropathy, and neuropathy compared with conventional therapy of one
or two daily insulin injections over a 6.5-year period [11–14]. However, an increased occurrence of
severe hypoglycemia was evident with intensive treatment compared to the conventional arm [15].
Thus, more frequent finger prick sampling is inconvenient for patients, increases cost to healthcare
providers, and might still not stabilize glycemic control.
In recent years, devices that monitor glucose levels continuously offer opportunities for painless
observations of glucose that may guide better glucose management in the daily life of people with
type 1 diabetes [16]. Emerging work now demonstrates longitudinal improvements in glucose
management with the use of continuous glucose monitoring systems in the daily life of people
with type 1 diabetes [17]. Flash glucose monitoring systems, similar to continuous glucose monitoring
systems, are now available on prescription in the UK NHS for patients with type 1 diabetes. Current
devices monitor dynamic interstitial glucose information for up to two weeks without the need for
confirmatory finger prick blood glucose measures. However, whilst mean absolute relative differences
demonstrate strong similarity to reference blood values [18], these data are generally reported during
rest and not during dynamic exercise.
Performing an acute bout of exercise evokes rapid changes in many physiological systems and
demands constant adjustment to facilitate glucose provision to the exercising tissues in both healthy
individuals and people with type 1 diabetes [10,19]. The net exercise-induced glucose response in the
circulation results from changes in carbohydrate ingestion, hepatic release and uptake, skeletal muscle
and adipose tissue uptake (amongst other organs), or hepatic gluconeogenesis, and is dependent
on the exercise characteristics: type, mode, intensity, and duration [20–23]. Importantly, (and often
overlooked) acute exercise also causes significant redistribution in body fluid between the interstitium,
lymphatics, and bloodstream [24]. Changes in posture, sweating, muscle contraction, and hydration
dramatically impact interstitial fluid volume and result in altered concentrations of glucose due to
fluid redistribution within this compartment.
This review does not seek to revise the historical development of interstitial glucose monitoring
technology or its inclusion around physical activity per se but rather seeks to focus on our current
understanding of acute physiological changes around exercise involving the interstitium and device
performance around acute physical exercise in individuals with type 1 diabetes. A firm understanding
of the complex physiological adaptations to acute exercise may inform the reader of the strengths and
limitations in tracking glucose using continuous and flash monitoring systems in a dynamic metabolic
environment such as exercise and offer more confidence for people with type 1 diabetes to better
manage glycemia around exercise.
2. Physiological Adjustments to Increased Blood Flow and Glucose Provision during
Physical Exercise
2.1. Initiation of Physical Exercise
Complex physiological adaptations dictate the ability of skeletal muscle to generate and maintain
power in healthy individuals and people with type 1 diabetes [25,26]. The cardiorespiratory system
plays a critical role in facilitating increased provision of glucose and oxygen (alongside the removal of
carbon dioxide and other metabolic by-products) to exercising muscle. Yet, physical exercise begins
with mental activity! In the brain, increased nerve impulses from the cerebral cortex act on the medulla
oblongata and suppress vagal tone to stimulate an increase in cardiac output (i.e., heart rate × stroke
volume) from ~5 L/min at rest to over 25 L/min in individuals with type 1 diabetes [27]. Central brain
areas also raise the baroreflex level to allow blood pressure regulation at a higher set-point, which
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facilitates higher sympathoadrenal activity and allows further increases in cardiac output. Skeletal
muscle arterioles dilate via the actions of increased circulating catecholamines and sympathetic nerve
activity on vascular β-adrenoceptors [20]. In non-active splanchnic and renal beds, a greater vascular
constriction occurs to allow more blood to flow to exercising areas [27].
2.2. Continuation of Physical Exercise
As exercise continues, cardiovascular and respiratory systems continuously adjust to the exercise
workload to ensure glucose- and oxygen (O2)-rich blood reaches working muscles at the required
rate. Elevated cerebral motor center activity and skeletal muscle afferent fiber mechanical (tension)
and metabolic (e.g., H+, K+, and local ischemia) signals stimulate sympathetic nervous system
activity and causes increases in circulating catecholamines that act on adrenoceptors on vessels
and skeletal muscle cells and consequently vasodilation in healthy individuals [28]. Local to the
exercising muscle and heart, metabolites cause vasodilation of skeletal muscle and coronary arterioles.
This exercise-induced hyperemia or ‘exercise pressor reflex’ decreases vascular resistance and increases
blood flow concomitant with increased capillary recruitment [29]. In high-intensity activities such
as sprinting or strength exercises that involve a Valsalva-type maneuver, vascular compression and
decreased blood flow induce the buildup of metabolites that activate chemoreceptors, resulting in
a greater exercise pressor reflex than dynamic activities, and cause increased cardiac output, total
peripheral resistance, and tachycardia that alters blood flow rate in healthy individuals [29]. Increased
sympathoadrenal activity constricts arterioles in the non-exercising areas. Also, exercise-induced
sympathoadrenal activity increases suppression of vagal activity proportional to the exercise intensity
and vasoconstriction of the smooth muscle arterioles. Cutaneous blood flow is initially reduced
via vasoconstriction but then increases as vasodilatation occurs due to a rise in body temperature
to promote cooling [20]. However, with long duration high-intensity exercise, cutaneous perfusion
may again fall as vasoconstriction re-diverts blood flow to muscle. Brain blood flow tends to remain
largely constant. During inspiration, pressure in the thoracic cavity falls. With diaphragm contraction
during inspiration, there is an increased abdominal pressure that compresses veins and venous blood
flow in the abdomen and drives blood back to the heart [30]. The thoracoabdominal pump is also
appreciable during heavy exercise as tidal volume and breath frequency increase ventilation rates to
over 150 L/min, which was observed in healthy and diseased individuals.
2.3. Blood Flow Distribution to Skeletal Muscle during Exercise
At rest, around two-thirds of the blood volume is present in veins and most capillaries are
closed; blood flow rates to skeletal muscle is approximately 20–30 mL·min−1·kg muscle−1 at an
open capillary density of ~100 capillaries per mm2 in healthy individuals [31]. During exercise, open
capillaries increase five-fold due to vasodilation from sympathoadrenal activity and locally from factors
emanating from skeletal muscle metabolism (decrease in pO2, rise in pCO2, decreased pH, temperature,
adenosine, NO, Pi, K+). Thus, increased cardiac output and localized vasodilation together account for
up to a 100-fold increase in blood flow to working tissues (2–3 L·min−1·kg muscle−1 during heavy
exercise). Further, to facilitate this increased rate of blood flow, a rapid shunting of venous blood to the
arterial circuit occurs by vasoconstriction of major veins.
Notwithstanding rapid blood redistribution within the circulation, plasma volume may fall ~20%
(1 L) with intense exercise over 15 min due to fluid movement towards active muscle [28]. Alterations
in the osmolarity of skeletal myocyte cytoplasm and interstitial fluid due to local release of metabolic
factors from skeletal muscle increase solutes in the interstitial fluid [28]. Also, an increased perfusion of
capillary beds in active muscle increases capillary hydrostatic pressure, which drives more fluid from
the plasma to the interstitium [20]. The extent of plasma volume reduction can be magnified by the
ambient temperature and humidity and offset by oral consumption of fluids. The overall effect of a net
loss in plasma volume is an apparent increase in red blood cell count and hemoglobin concentration,
which increases the O2-carrying capacity per liter of blood, but at the expense of a reduction in total
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blood volume and an increase in viscosity. The movement of fluid from the plasma to the interstitium
is offset to a certain extent by fluid movement back into the circulation from tissues that undergo
vasoconstriction (gut, kidneys) [32].
3. The Interstitial Compartment and Factors Influencing Movement of Interstitial Fluid
during Exercise
The interstitial space lies between the circulatory system and organs such as skeletal muscle,
myocardium, and liver and contains approximately three-quarters of the body’s total extracellular
fluid (e.g., ~10–12 L in a 70-kg person) [33]. Plasma and lymph fluid represent most of the remaining
quarter (~3 L) of extracellular fluid. Interstitial fluid represents a quarter of total body water mixing
with plasma, lymph fluid, and sweat [33].
The factors that determine the speed and magnitude of movement of fluid between capillaries
and interstitium are determined by Starling forces [34]. The net filtration pressure (NFP) is determined
by two pressure differentials that determine the net drive for directional fluid movement between the
capillary and interstitial space, namely:
(i) Colloid osmotic pressure between capillary (Pc) and interstitial space (Pif)
Capillary colloidal pressure is exerted by proteins such as albumin, which causes fluid to be pulled
back into the capillary at the venous end due to a higher solute concentration [35]. The remaining
fluid left in the interstitial space is drained by the lymphatic capillaries and returned to the circulation.
The interstitial colloidal pressure is regulated by the interstitial fluid concentration and the permeability
of the capillary to different proteins. As plasma contains more protein than the interstitial fluid,
capillary colloidal pressure tends to dominate all the way along the capillary wall [35].
(ii) Hydrostatic pressures from capillary (pic) to interstitial space (piif)
Colloidal hydrostatic pressure is exerted by the plasma fluid against the capillary wall, moving
the fluid into the interstitium through filtration and is greater at the arterial end of a capillary due to
the higher blood pressure [36]. The interstitial hydrostatic pressure is determined by the interstitial
fluid volume and the surrounding tissues’ compliance with changes in volume and pressure; skin
and skeletal muscle have higher compliance to changes in volume and pressure with more soft tissue
surrounding them than the brain [37].
Thus, net filtration pressure (NFP) = Pc + piif − Pif − pic and the transendothelial fluid filtration
rate (cm3/s) is represented by Equation (1):
Jv = LpS [(Pc − Pif) − σ(pic − piif)] (1)
where
• Lp is the hydraulic conductivity (which provides a measure of water permeability; m2·s·kg−1 or
m·s−1·mmHg−1);
• S is the surface area available for fluid exchange in m2;
• σ is the osmotic reflection coefficient (dimensionless unit) where σ close to 1.0 indicates the
capillary is fully effective in allowing fluid and smaller solutes to filter to the interstitial space
while larger protein molecules such as albumin are retained. Where σ is <1.0, capillary filter
function is reduced.
Acute physical exercise does not alter the characteristics of the microvascular exchange
vessels [38–40]. Thus, S (the surface area available for fluid exchange) contributes most to the enhanced
filtration rates with acute exercise but alterations in hydraulic conductivity (Lp) and/or the osmotic
reflection coefficient (σ) do not.
Although most pressure fluctuations are absorbed at the level of precapillary resistance vessels,
even modest increases in capillary filtration drive lead to fluid accumulation in the interstitial
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compartment and can increase from 0.008–0.015 mL/min/mmHg for resting skeletal muscle to greater
than 4-fold during exercise in healthy individuals [24]. Thus, the rate of fluid filtration from the
blood to the tissue interstitial space can reach 1.5 mL·min−1·100 g muscle−1 during intense rhythmic
contraction [39–42]. This rapid rate of fluid movement with exercise initially exceeds the drainage
capacity of the lymphatic system and, converse to the loss of plasma fluid, is a gain in interstitial fluid
volume of ~15–20% in exercising tissue [43]. This is due to several factors: (i) exercise-induced capillary
hydrostatic pressure increasing with arteriolar vasodilation [43]; (ii) relaxation of vascular smooth
muscle in arterioles increasing capillary surface area by recruiting capillaries that were previously
closed [41]; and (iii) a muscular contraction-induced increase in interstitial fluid osmolarity due to
released metabolites (e.g., K+, lactate, H+, adenosine, ammonia) from active skeletal muscle cells that
transiently raises interstitial fluid osmolarity by ~20–30 mmol/L or 7–10% [41]. Also, an expanded
interstitial fluid volume increases the diffusion distance for glucose molecules and may hinder cellular
metabolism in swollen tissues. Interstitial (or cellular) edema can also impair glucose tissue perfusion
by collapsing capillaries in swollen tissue [44].
The initial rate of hypervolemia in the interstitium slows as exercise continues due to (i) a
compensatory absorption of interstitial fluid by vasoconstricted vascular beds where capillary pressure
is lower in non-exercising tissues; and (ii) the subsequent reduction in flow rate allows better lymphatic
drainage [43] with one-way flow [44] and flow-induced lymphatic dilation. Muscle contraction
increases interstitial fluid pressure and reduces the transcapillary hydrostatic gradient, further reducing
fluid accumulation with sustained exercise [45].
4. Interstitial Glucose Metabolism during Exercise
The small amount of glucose in the interstitium of an adult individual with type 1 diabetes
(e.g., 10 mmol/L = 1.8 g/L = 18 g with an interstitial fluid volume of 10 L) represents the point
measurement of glucose changes at that measured site. Patients in a fasted, resting state produce small
rate changes in the disappearance and/or appearance of glucose. However, acute exercise dramatically
increases carbohydrate combustion and the metabolic turnover [46] of glucose increases 40 to 50-fold in
exercising tissues (Table 1) [33,47]. The magnitude of change in interstitial glucose with acute physical
exercise in people with type 1 diabetes is dependent on the type, mode, intensity, and duration of
exercise, as well as the time of day, circulating insulin levels, and whether the individual is fasted
or fed.
Table 1. Glucose transport from blood to skeletal muscle (per 110/g) [33,47].
Rest HeavyExercise
Fractional ∆
(Exercise/Rest)
Skeletal muscle glucose consumption (Js), µmol/min 1.4 60 ×43
Arterial glucose concentration (Ca), mM 5.0 5.0 -
Venous concentration (Cv), mM 4.4 4.0 ×0.9
Extraction E, % 11.2 20 ×1.8
Blood flow, mL/min 2.5 60 ×24
Perfused capillary density, per mm2 250 1000 ×4
Diffusion capacity (PS), cm3/min 5 20 ×4
Mean concentration difference across capillary wall (∆C = Js/PS), mM 0.3 3.0 ×10
Mean pericapillary concentration (Ci), mM 4.7 2.0 ×0.4
Krogh Cylinder radius, µm 36 18 ×0.5
4.1. Glucose Transport to Exercising Muscle
Capillary recruitment shortens the diffusion distance and increases the surface area, with the
diffusional capacity increased further by an effect of blood flow on permeability. A fall in tissue glucose
concentrations raises the gradient across the capillary wall and the increase in diffusional flux raises
the fractional extraction and arteriovenous concentration difference (Ca-Cv) [48]. An increased blood
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flow delivers glucose faster to the capillary and prevents a major fall in the mean intra-capillary plasma
concentration, thereby avoiding a flow-limitation of exchange. The new trans-capillary glucose flux is,
thus, determined from the Fick principle equaling blood flow × increased arteriovenous concentration
difference (Table 1) [48].
4.2. Exercising Skeletal Muscle Tissue Is a Glucose Consumer; Inactive Tissue Acts as a Glucose Store
Glucose entry into muscle occurs across the cell membrane via the glucose transporter type-4
(GLUT-4) [49]. Once inside the muscle, glucose is irreversibly converted to glucose 6-phosphate via
the enzyme hexokinase to prevent loss of this valuable nutrient from muscle and is either utilized via
glycolysis or stored as glycogen until needed [49]. Skeletal muscle glycogen stores are about 300–350 g
and can be manipulated with low carbohydrate diets to reduce estimated whole-body stores from 300
to 50 mmol·glucosyl units per kg−1 wet weight in healthy individuals [50]. Conversely, short-term
high carbohydrate diets markedly increase muscle glycogen stores to more than 500 mmol·glucosyl
units per kg−1 wet weight. Carbohydrate combustion in the absence of oxygen is important for
releasing energy during high-intensity exercises such as sprinting or strength exercises. For example,
a 6 second cycle sprint reduces quadriceps muscle glycogen concentration by 14% from 316 ± 75
to 273 ± 80 mmol·glucosyl units per kg−1 wet weight [51] and by 32% after a 30 second sprint [21].
Consequently, blood lactate and H+ concentrations increase from ~1.0 to over 20 mmol/L and 7.4 to
<7 pH units and alters osmolarity in the interstitial space [21,51]. The net glucose uptake into tissues
during exercise depends on the exercise characteristics; moderate intensity exercise causes similar
whole-body rates of glucose appearance and disappearance. In contrast, high-intensity exercise causes
a disproportionate rate of increase in glucose appearance compared to disappearance [52].
4.3. Hepatocytes Take Up and Release Glucose
The liver glycogen content is approximately 80–110 g for a 70-kg person and similar to
muscle is easily manipulated with low carbohydrate diets, reducing hepatic stores from 232 to
24–55 mmol·glucosyl units per kg−1 wet weight within 24 h in healthy people [53]. Conversely,
high carbohydrate diets markedly increase hepatic glycogen stores to supernormal values of
424–624 mmol·glucosyl units per kg−1 wet weight [53], especially if preceded by glycogen-depleting
exercise, a concept known as glycogen supercompensation [50]. In contrast to skeletal myocytes,
hepatocytes contain a phosphatase enzyme that catalyzes stored glucose, allowing the glucose to
leave the liver cell and enter the interstitial space prior to appearing in the circulation. A strong
counter-regulatory hormone response elicited by high-intensity exercise acts on hepatocytes to
promote hepatic glucose release and consequent exercise-induced hyperglycemia in people with
type 1 diabetes [54]. Carbohydrate combustion in the presence of oxygen can increase from resting
values of ~0.25 g/min to over 3.0 g/min and the liver plays an important role in the later stages
of endurance exercise to support exercise metabolism beyond that of lipid [20]. On the other hand,
one day of starvation and/or prolonged exercise might almost deplete endogenous carbohydrate
stores, excepting for the body’s ability to minimize this loss through the manufacture of new glucose
from amino acids, ketoacids, or lactate in the liver; the contribution of gluconeogenesis to exercise is
important [20,22].
4.4. Exogenous ‘On-Board’ Insulin Concentrations Differ When Compared with Endogenous Insulin
In people that do not have diabetes, plasma insulin falls with exercise duration and/or intensity
due to exercise-induced catecholamine inhibition on pancreatic ß-cell function [55]. However, no such
reductions on exogenous insulin are seen in individuals with type 1 diabetes. Indeed, there is evidence
of increased circulating insulin with exercise [56]. Insulin stimulates vasodilation around subcutaneous
depots where injected insulin may be flushed into the extracellular space and increase glucose uptake
and hepatic glucose inhibition [57].
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4.5. Ingested Carbohydrate from the Gastrointestinal Tract
Ingested carbohydrates (e.g., a mixture of glucose and fructose) can be assimilated from the small
intestine at an upper limit of ~1.8 g/min [58]. Interestingly, glucose alone can be absorbed and utilized
at rates of ~1.0–1.1 g/min, due to rate limits in the capacities of the glucose transporter type-2 (GLUT-2),
glucose transporter type-5 (GLUT-5), and/or sodium–glucose linked transporter-1 (SGLT-1) carriers in
the intestinal membrane [59]. In people with type 1 diabetes, carbohydrate ingestion in readiness for
exercise increases blood glucose with the overall magnitude dependent on factors such as amount,
digestibility, and glycemic index [6]. This new glucose appearance into body fluid compartments alters
body fluid osmolarity.
5. Interstitial Glucose Responses to Different Forms of Exercise
Continuous glucose monitoring systems use an enzymatic technique that reacts with circulating
glucose in the interstitium [60]. This reaction releases one electron for each glucose molecule and
transmits it to an electrode. Within this electrode, an electric current is generated that is passed from a
transmitter (attached or incorporated) to a reader (e.g., mobile phone) to reflect the interstitial glucose
levels [60].
Data on head-to-head comparisons between continuous and flash glucose monitoring systems
remain rare. Aberer et al. [61] have shown that the Abbott FreeStyle Libre (Abbott, Alameda, CA,
USA) flash glucose monitoring system was the most accurate (median absolute relative differences
(MARD) 8.7 ± 5.9%, n = 13), followed by Dexcom G4 Platinum (Dexcom, San Diego, CA, USA)
(MARD 15.7 ± 14.6%, n = 24), and Medtronic MiniMed 640 G (Medtronic MiniMed, Inc., Northridge,
CA, USA) (MARD 19.4 ± 13.5%, n = 22) during 30 min (2 × 15 with a 5 min rest) of low-intensity
continuous exercise. However, it must be mentioned that only thirteen comparison points between
blood glucose and interstitial glucose concentrations were available for the flash glucose monitoring
system. Unfortunately, in this trial, glucose concentrations were not classified for hypo-, eu-,
and hyperglycemia during exercise. Disagreements in absolute glucose values during exercise
between different compartments were found in healthy individuals [62] and in patients with type 1
diabetes [63–65]. Interstitial glucose concentrations measured via the SEVEN® PLUS CGM (Dexcom,
San Diego, CA, USA) system during exercise under euglycemic conditions are higher compared to
capillary (finger sticks) and venous blood, and the capillary blood levels seem to be higher than
the venous blood levels [62]. In patients with type 1 diabetes performing high-intensity interval
exercise and continuous exercise, no clear trend was found in comparing the capillary blood glucose
concentration (earlobe) and interstitial glucose concentration when using the Guardian REAL-time
system and the Enlite sensor (Medtronic MiniMed, Inc., Northridge, CA, USA) (no classification for
glycemic ranges was performed) [63]. However, in a different study comparing the interstitial glucose
(G4 Platinum, Dexcom, San Diego, CA, USA) and venous blood glucose concentration, a trend towards
lower levels were found in venous blood when exercising within a euglycemic range (blood glucose
during high-intensity interval exercise: 7.56 ± 0.21; blood glucose during continuous exercise: 6.71
± 0.23) [64]. Interestingly, significantly lower glucose concentrations were found in the interstitium
compared to the venous system for continuous exercise and for resistance exercise under a euglycemic
range when using the CGMS® System Gold® (Medtronic MiniMed, Inc., Northridge, CA, USA) [65].
The duration of exercise seems not to influence the differences in glucose levels in different
compartments [63–65]. However, it might be that longer-duration exercise and the potential for
dehydration could decrease the glucose supply within the interstitium, resulting in lower glucose
levels compared to the capillary and venous systems. Furthermore, the lag time in interstitium
could be influenced by the intensity of exercise and the amount of circulating insulin. Low insulin
reductions combined with high exercise intensities could increase the lag time between the blood and
the interstitium, resulting in severe impairments for continuous and flash glucose monitoring systems.
The type and mode of exercise seem not to influence continuous glucose monitoring accuracy [63–65].
During high-intensity interval exercise and continuous exercise, continuous glucose monitoring
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technology shows sufficient potential to trace changes in glucose concentrations [63,64]. During
resistance exercise, a mean difference of −0.71 mmol/L was found [65]. However, it should be
considered that during resistance exercise the site of sensor placement might directly influence its
performance. Therefore, it is prudent to place the sensor away from working muscles.
Only a single study assessed continuous glucose monitoring accuracy during exercise under
hypoglycemic conditions [66]. When a hypoglycemic alarm was set at 5.5 mmol/L, the system
overestimated the interstitial glucose by 1.6 mmol/L. Therefore, a higher alarm level setting is
recommended to avoid exercise-induced hypoglycemia.
Future research should clearly evaluate sensor performance under hypo-, eu-, and hyperglycemic
ranges during exercise. Additionally, reported sensor performance during exercise needs to be adjusted
for any treatments (e.g., carbohydrate ingestion, bolus insulin correction).
6. Continuous and Flash Glucose Monitor Performance
Twenty years of intensive research reveal marked improvements in continuous glucose monitoring
performance in the reflection of accuracy, precision, and reliability. Since the start of the millennium,
MARDs have been halved from 20% to 10% [67,68]. The Dexcom G5TM Mobile continuous glucose
monitoring system, which is approved for patients aged two years and older, shows a MARD of 9% for
adults and 10% for pediatric patients [68]. Sensor lifetime is 7 days accompanied with 2 calibrations
to capillary blood glucose concentration per day. Its predecessor model, the Dexcom G4® system
(Dexcom, San Diego, CA, USA), was found to be less accurate with MARDs of 13% for adults and
15% for pediatric patients [69–72]. Sensor lifetime is also 7 days, accompanied with 2 calibrations to
capillary blood glucose concentration per day.
Medtronic’s (Medtronic MiniMed, Inc., Northridge, CA, USA) flagships are the MiniMed 670 G
hybrid closed-loop system and 640 G with SmartGuard® (predictive low glucose), as well as the
Medtronic Paradigm Minimed Veo® (530 G) with low glucose suspend. Recently, the MARD for the
Medtronic 640 G system was found at 9.6%, using the GuardianTM sensor 3 [73]. Predecessor models
using EnliteTM sensor technologies resulted in MARDs of 13.6–14.2% for adults and of about 21%
for children from 4–14 years for blood glucose levels below 6.7 mmol/L [72,74]. Sensors need to be
changed after 6 days, requiring 2 calibrations per day.
A slightly different technology, Abbotts FreeStyle® Libre FGM system (Abbott, Alameda,
CA, USA), was also found to track changes in interstitial glucose accurately with a MARD
of 10–11.4% [18,72]. This device shows a sensor lifetime of 14 days and is factory-calibrated.
The FreeStyle® Navigator II CGM system has a MARD of 12.3% with a sensor lifetime of up to
5 days and needs to be calibrated 3–4 times per day [72].
Notable, a novel analytical framework that enables spectroscopy-based longitudinal tracking of
blood glucose without extensive a priori information was investigated by Spegazzini et al. [75]. Using
blood glucose monitoring by Raman spectroscopy as an example, it was found that the efficacy of this
approach was comparable to conventional calibration methods (35% reduction in error over partial
least squares regression when applied to glucose tolerance tests).
7. Continuous and Flash Glucose Monitoring Systems’ (Dis) Advantages and Exercise
These commonly used devices reveal different advantages and disadvantages for daily life;
furthermore, accuracy during exercise might be divergent to general MARDs (Table 2).
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Table 2. Advantages, disadvantages, and exercise performance in continuous and flash glucose
monitoring systems.
Advantage Disadvantage Exercise Performance
Dexcom G5TM
Hypo- and hyperglycemia alerts; rise and
fall (rate of change) alerts; compatible with
mobile devices; online live monitoring with
different mobile devices (e.g., for parents),
CE 1 mark
(European Union). Approved for
non-adjuvant use; compatible with Apple
iPhone 4S and subsequent iOS models
Requires calibration to
blood glucose; no
integrated bolus wizard
N/A for Dexcom G5TM
Dexcom G4TM
Hypo- and hyperglycemia alerts; rise and
fall (rate of change) alerts; available
integrated with the Animas Vibe pump
Requires calibration to
blood glucose; no
integrated bolus wizard
Continuous exercise:
MARD 2 13.6–18.6%;
interval exercise: MARD
13.3–17.7% [61,64,76]
(interstitial glucose
compared to venous
plasma glucose)
Medtronic
670 G with
SmartGuard®
Hybrid closed-loop system when combined
with insulin pump (automatic insulin
delivery when glucose is high); predictive
low glucose-suspend when combined with
insulin pump; predictive low glucose alert;
hypo- and hyperglycemia alerts; rise and
fall (rate of change) alerts; Bluetooth
connected to glucometer (CONTOUR,
NEXT LINK 2.4); bolus wizard
Requires calibration to
blood glucose
N/A 3 for this specific
system
Medtronic
640 G with
SmartGuard®
Predictive low glucose-suspend when
combined with insulin pump; predictive
low glucose alert; hypo- and hyperglycemia
alerts; rise and fall (rate of change) alerts;
Bluetooth connected to glucometer
(CONTOUR, NEXT LINK 2.4); bolus
wizard
Requires calibration to
blood glucose
Continuous exercise:
MARD 19.4% [61]
(interstitial glucose
compared to venous
plasma glucose)
Medtronic
Paradigm
Minimed® Veo
(530 G)
Low-glucose-suspend when combined with
insulin pump; hypo- and hyperglycemia
alerts; rise and fall (rate of change) alerts;
Bluetooth connected to glucometer
(CONTOUR, NEXT LINK 2.4); bolus
wizard;
Requires calibration to
blood glucose
Continuous exercise:
MARD 12.8–23.7%;
interval exercise: MARD
15.5–26.5% [63]
(interstitial glucose
compared to capillary
blood glucose)
FreeStyle®
Libre Flash
glucose
monitoring
Factory-calibrated; long sensor lifetime
(14 days); integrated glucometer; integrated
blood ketone measurement; cheap sensor
costs; integrated bolus wizard
No automatic hypo- or
hyperglycemia alerts; not
combinable with pump
Continuous exercise:
MARD 8.7% [61]
(interstitial glucose
compared to venous
plasma glucose)
FreeStyle®
Navigator II
CGM system
30 m transmission range; new result every
minute; hypo- and hyperglycemia alerts;
early warning alarms; integrated
glucometer
Fixed time points for
calibration: 1, 2, 10, 24,
and 72 h after sensor
insertion
N/A for the second
generation
1 CE (Conformité Européenne) marking is a certification mark that indicates conformity with health, safety, and
environmental protection standards for products sold within the European Economic Area. 2 MARD: Median
Absolute Relative Difference. 3 N/A: Not Applicable.
8. Continuous and Flash Glucose Monitor Algorithms
As continuous and flash glucose monitoring systems measure glucose within the interstitial fluid,
a certain lag time is present for the glucose to diffuse from the blood into the interstitium. To overcome
this lag time and to reduce the risk of inadequate therapy decisions (e.g., overdose in bolus insulin
correction), several algorithms are incorporated in continuous and flash glucose monitoring systems.
Generally, so-called algorithmically “smart sensors” incorporate three software modules that need to
work in real time [77,78]:
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• denoising the random noise component
• enhancing the accuracy
• predicting the future glucose concentration
As used by Facchinetti et al. [77], an adaptive self-tunable Bayesian smoother is able to
automatically estimate the signal-to-noise ratio present in the continuous glucose monitoringdata [79].
For the enhancement of accuracy, a stochastic deconvolution-based re-calibration algorithm is applied,
which re-scales the interstitial glucose data using a simple linear regressor whose parameters are
re-calculated for each self-measured blood glucose value [78,80]. Especially this or a similar denoising
and enhancement algorithm is inwrought in the Dexcom (Dexcom, San Diego, CA, USA) G4 and G5
sensor technology (505 algorithm).
Predicting future glucose concentrations is based on an autoregressive model of order, one
based on the findings of Sparacino et al. [81]. For example, the Medtronic 640 G with SmartGuard®
(Medtronic MiniMed, Inc., Northridge, CA, USA) uses an algorithm that predicts the decrease of
20 mg/dL within the next 30 min above the pre-defined “low-threshold”. When combined with an
insulin pump, it suspends the infusion of insulin before reaching this value and automatically restarts
when it predicts that glucose levels will increase by 20 mg·dL−1 above the pre-defined low glucose
threshold [78].
9. Future Directions
9.1. Artificial Pancreas
In line with a recent review, a threshold low-glucose suspend of insulin infusion might be
the first step towards an artificial pancreas [72]. The future of artificial pancreas devices promises
a more accurate mimicking of endogenous responses to glucose fluctuations; achieved via dual
hormone closed-loop systems using insulin and glucagon [82,83]. This system is able to reduce
significantly hypoglycemic episodes. Intriguingly, the beneficial effects of dual- compared to single
hormone closed-loop systems were observed during continuous and interval exercises [84]. In this
study, glucagon was given a microboluses to avoid drastic increases in blood glucose concentrations.
Glucagon delivery was based on logical rules considering glucose concentration estimates and their
trends. Importantly, the insulin delivery algorithm took account of the injected glucagon onboard via
the dual-hormone artificial pancreas. During continuous exercise, a total glucagon dose of 0.126 ±
0.057 mg was administered and during interval exercise 0.093± 0.068 mg. The split total glucagon dose
was delivered every 10 min during the 60 min exercise sessions. Mini-doses of glucagon were found
to be efficacious and safe to treat mild hypoglycemia in adults with type 1 diabetes [85]. Successful
hypoglycemia-treatment criteria were met for 94% when using a mini-dose of glucagon in comparison
to 95% when giving oral glucose tablets.
Instead of glucagon selective antagonism of somatostatin receptor type 2 (SSTR2) might also
be reasonable (within the artificial pancreas) [86]. SSTR2 antagonism after recurrent hypoglycemia
ameliorates the glucagon and corticosterone responses, as well as decreases the risk of insulin-induced
hypoglycemia in rats with type 1 diabetes. However, a safety profile of SSTR2 antagonism will need
to be established. Potential adverse effects might be increased gastric acid secretion and effects on
pituitary and adrenal hormone secretion [87].
In real life, the only commercially available system (FDA approved), which is similar to an
artificial pancreas, is the hybrid closed-loop system from Medtronic (670 G with SmartGuard®)
(Medtronic MiniMed, Inc., Northridge, CA, USA). However, from the authors’ point of view, the
fundamental problem in the development of a “real” artificial pancreas might be the sensor inaccuracy
and sensor/interstitial glucose lag time to blood glucose concentration. For example, the Abbott
FreeStyle Libre (Abbott, Alameda, CA, USA) flash glucose monitoring system shows an average lag
time of 4.5–4.8 min (for both clinic and home-phases) [18]. In a rapidly changing internal environment
during acute exercise combined with low doses of circulating bolus insulin this lag time could
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potentially rise by 200%, as observed in our lab in two ongoing clinical trials (U1111-1174-6676;
DRKS00013477). Furthermore, if the artificial pancreas is designated to work autonomously, the use of
detectors of physical activity (e.g., heart rate monitor, accelerometer, small spirometry devices) needs
to be incorporated from the very early stages of development.
9.2. Implantable Sensors
In a recent pivotal study, the MARD of the Eversense implantable continuous glucose monitoring
sensor (Senseonics Inc., Germantown, MD, USA) was found at 11.1% against reference glucose values
above 4.2 mmol/L [88]. Implantable continuous glucose monitoring systems may provide advantages
since frequent sensor insertions are not needed and the transmitter can be removed without sensor
replacement. However, the implantation and removal are a minor surgical procedure and accompanied
by some discomfort.
10. Conclusions
As more health services and insurance companies advocate their use, understanding continuous
and flash glucose monitoring systems for its strengths and limitations around exercise may offer more
confidence for patients aiming to better manage glycemia. This review detailed the complexities of
acute physical exercise and offers an integrated understanding of the efficacy of glucose monitoring
with current technology around a heightened metabolic state such as exercise.
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